JP2018511583A - 乳酸菌由来の細胞外ベシクルを有効成分として含む、炎症疾患の予防または治療用の組成物 - Google Patents
乳酸菌由来の細胞外ベシクルを有効成分として含む、炎症疾患の予防または治療用の組成物 Download PDFInfo
- Publication number
- JP2018511583A JP2018511583A JP2017547484A JP2017547484A JP2018511583A JP 2018511583 A JP2018511583 A JP 2018511583A JP 2017547484 A JP2017547484 A JP 2017547484A JP 2017547484 A JP2017547484 A JP 2017547484A JP 2018511583 A JP2018511583 A JP 2018511583A
- Authority
- JP
- Japan
- Prior art keywords
- lactic acid
- acid bacteria
- derived
- extracellular vesicles
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title claims abstract description 274
- 241000894006 Bacteria Species 0.000 title claims abstract description 234
- 239000004310 lactic acid Substances 0.000 title claims abstract description 137
- 235000014655 lactic acid Nutrition 0.000 title claims abstract description 137
- 239000000203 mixture Substances 0.000 title claims abstract description 60
- 208000027866 inflammatory disease Diseases 0.000 title claims abstract description 44
- 239000004480 active ingredient Substances 0.000 title claims abstract description 27
- 206010012438 Dermatitis atopic Diseases 0.000 claims abstract description 99
- 201000008937 atopic dermatitis Diseases 0.000 claims abstract description 99
- 210000002700 urine Anatomy 0.000 claims abstract description 51
- 238000000034 method Methods 0.000 claims abstract description 33
- 238000009826 distribution Methods 0.000 claims abstract description 32
- 208000006673 asthma Diseases 0.000 claims abstract description 21
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims abstract description 17
- 230000036541 health Effects 0.000 claims abstract description 17
- 239000002537 cosmetic Substances 0.000 claims abstract description 16
- 235000013376 functional food Nutrition 0.000 claims abstract description 15
- 210000004369 blood Anatomy 0.000 claims abstract description 13
- 239000008280 blood Substances 0.000 claims abstract description 13
- 206010009137 Chronic sinusitis Diseases 0.000 claims abstract description 11
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims abstract description 11
- 206010039083 rhinitis Diseases 0.000 claims abstract description 11
- 230000002265 prevention Effects 0.000 claims abstract description 7
- 241000186660 Lactobacillus Species 0.000 claims description 31
- 238000004458 analytical method Methods 0.000 claims description 31
- 229940039696 lactobacillus Drugs 0.000 claims description 26
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 238000003752 polymerase chain reaction Methods 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 11
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 11
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 11
- 241000194036 Lactococcus Species 0.000 claims description 8
- 241000192132 Leuconostoc Species 0.000 claims description 8
- 206010040047 Sepsis Diseases 0.000 claims description 8
- 201000009151 chronic rhinitis Diseases 0.000 claims description 8
- 238000002405 diagnostic procedure Methods 0.000 claims description 5
- 230000006698 induction Effects 0.000 claims 1
- 241000589516 Pseudomonas Species 0.000 abstract description 17
- 206010061218 Inflammation Diseases 0.000 abstract description 16
- 230000004054 inflammatory process Effects 0.000 abstract description 16
- 239000003814 drug Substances 0.000 abstract description 11
- 230000001684 chronic effect Effects 0.000 abstract description 10
- 238000011161 development Methods 0.000 abstract description 7
- 210000004969 inflammatory cell Anatomy 0.000 abstract description 7
- 238000006243 chemical reaction Methods 0.000 abstract description 5
- 238000000338 in vitro Methods 0.000 abstract description 5
- 238000002474 experimental method Methods 0.000 abstract description 4
- 241000295644 Staphylococcaceae Species 0.000 abstract description 3
- 210000002919 epithelial cell Anatomy 0.000 abstract description 3
- 206010051739 Pulmonary sepsis Diseases 0.000 abstract description 2
- 238000001727 in vivo Methods 0.000 abstract description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 25
- 108020004414 DNA Proteins 0.000 description 23
- 210000002966 serum Anatomy 0.000 description 23
- 102000004889 Interleukin-6 Human genes 0.000 description 20
- 108090001005 Interleukin-6 Proteins 0.000 description 20
- 230000001580 bacterial effect Effects 0.000 description 17
- 230000028327 secretion Effects 0.000 description 17
- 239000000523 sample Substances 0.000 description 13
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 210000004920 epithelial cell of skin Anatomy 0.000 description 10
- 239000006210 lotion Substances 0.000 description 10
- 108020004465 16S ribosomal RNA Proteins 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 9
- 102100040247 Tumor necrosis factor Human genes 0.000 description 9
- 208000026935 allergic disease Diseases 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 8
- 238000010172 mouse model Methods 0.000 description 8
- 210000003024 peritoneal macrophage Anatomy 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 238000012790 confirmation Methods 0.000 description 7
- 238000002296 dynamic light scattering Methods 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 102000001554 Hemoglobins Human genes 0.000 description 6
- 108010054147 Hemoglobins Proteins 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 208000037976 chronic inflammation Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 230000002458 infectious effect Effects 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- -1 synoxate Chemical compound 0.000 description 6
- 208000002874 Acne Vulgaris Diseases 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 102000013691 Interleukin-17 Human genes 0.000 description 5
- 108050003558 Interleukin-17 Proteins 0.000 description 5
- 206010000496 acne Diseases 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 206010040882 skin lesion Diseases 0.000 description 5
- 231100000444 skin lesion Toxicity 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 241000186427 Cutibacterium acnes Species 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 241000180027 Pseudomonas cedrina Species 0.000 description 4
- 239000013566 allergen Substances 0.000 description 4
- 230000000172 allergic effect Effects 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 4
- 239000000428 dust Substances 0.000 description 4
- 230000029142 excretion Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 208000017520 skin disease Diseases 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 108091093088 Amplicon Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 208000019693 Lung disease Diseases 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 108020004682 Single-Stranded DNA Proteins 0.000 description 3
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 239000000686 essence Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000003928 nasal cavity Anatomy 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 3
- 229960001173 oxybenzone Drugs 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000010936 titanium Substances 0.000 description 3
- 229910052719 titanium Inorganic materials 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- 208000000884 Airway Obstruction Diseases 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 239000006137 Luria-Bertani broth Substances 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 241000186429 Propionibacterium Species 0.000 description 2
- 238000011804 SKH1 hairless mouse Methods 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241001493533 Streptophyta Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229960004784 allergens Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- MCPKSFINULVDNX-UHFFFAOYSA-N drometrizole Chemical compound CC1=CC=C(O)C(N2N=C3C=CC=CC3=N2)=C1 MCPKSFINULVDNX-UHFFFAOYSA-N 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- 235000021107 fermented food Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 229940125721 immunosuppressive agent Drugs 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- VAMXMNNIEUEQDV-UHFFFAOYSA-N methyl anthranilate Chemical compound COC(=O)C1=CC=CC=C1N VAMXMNNIEUEQDV-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000012130 whole-cell lysate Substances 0.000 description 2
- HEOCBCNFKCOKBX-RELGSGGGSA-N (1s,2e,4r)-4,7,7-trimethyl-2-[(4-methylphenyl)methylidene]bicyclo[2.2.1]heptan-3-one Chemical compound C1=CC(C)=CC=C1\C=C/1C(=O)[C@]2(C)CC[C@H]\1C2(C)C HEOCBCNFKCOKBX-RELGSGGGSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- MEZZCSHVIGVWFI-UHFFFAOYSA-N 2,2'-Dihydroxy-4-methoxybenzophenone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1O MEZZCSHVIGVWFI-UHFFFAOYSA-N 0.000 description 1
- WHQOKFZWSDOTQP-UHFFFAOYSA-N 2,3-dihydroxypropyl 4-aminobenzoate Chemical compound NC1=CC=C(C(=O)OCC(O)CO)C=C1 WHQOKFZWSDOTQP-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- TYYHDKOVFSVWON-UHFFFAOYSA-N 2-butyl-2-methoxy-1,3-diphenylpropane-1,3-dione Chemical compound C=1C=CC=CC=1C(=O)C(OC)(CCCC)C(=O)C1=CC=CC=C1 TYYHDKOVFSVWON-UHFFFAOYSA-N 0.000 description 1
- JGUMTYWKIBJSTN-UHFFFAOYSA-N 2-ethylhexyl 4-[[4,6-bis[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 JGUMTYWKIBJSTN-UHFFFAOYSA-N 0.000 description 1
- CNXZMGRWEYQCOQ-UHFFFAOYSA-N 2-methoxy-3-phenylprop-2-enoic acid Chemical compound COC(C(O)=O)=CC1=CC=CC=C1 CNXZMGRWEYQCOQ-UHFFFAOYSA-N 0.000 description 1
- HMKKFLSUPRUBOO-IUPFWZBJSA-N 3,4-dihydroxy-5-[3,4,5-tris[[(z)-octadec-9-enoyl]oxy]benzoyl]oxybenzoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC1=C(OC(=O)CCCCCCC\C=C/CCCCCCCC)C(OC(=O)CCCCCCC\C=C/CCCCCCCC)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(O)=O)O)=C1 HMKKFLSUPRUBOO-IUPFWZBJSA-N 0.000 description 1
- 241000588626 Acinetobacter baumannii Species 0.000 description 1
- 241001147780 Alicyclobacillus Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 238000000035 BCA protein assay Methods 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 108020004513 Bacterial RNA Proteins 0.000 description 1
- 208000031636 Body Temperature Changes Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- FMRHJJZUHUTGKE-UHFFFAOYSA-N Ethylhexyl salicylate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1O FMRHJJZUHUTGKE-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241000589323 Methylobacterium Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000040340 Oat mosaic virus Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 description 1
- 241000954716 Pseudomonas panacis Species 0.000 description 1
- 241000238711 Pyroglyphidae Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 201000002462 atopic dermatitis 3 Diseases 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 229960005193 avobenzone Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- XVAMCHGMPYWHNL-UHFFFAOYSA-N bemotrizinol Chemical compound OC1=CC(OCC(CC)CCCC)=CC=C1C1=NC(C=2C=CC(OC)=CC=2)=NC(C=2C(=CC(OCC(CC)CCCC)=CC=2)O)=N1 XVAMCHGMPYWHNL-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000003012 bilayer membrane Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- FQUNFJULCYSSOP-UHFFFAOYSA-N bisoctrizole Chemical compound N1=C2C=CC=CC2=NN1C1=CC(C(C)(C)CC(C)(C)C)=CC(CC=2C(=C(C=C(C=2)C(C)(C)CC(C)(C)C)N2N=C3C=CC=CC3=N2)O)=C1O FQUNFJULCYSSOP-UHFFFAOYSA-N 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012468 concentrated sample Substances 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- FDATWRLUYRHCJE-UHFFFAOYSA-N diethylamino hydroxybenzoyl hexyl benzoate Chemical compound CCCCCCOC(=O)C1=CC=CC=C1C(=O)C1=CC=C(N(CC)CC)C=C1O FDATWRLUYRHCJE-UHFFFAOYSA-N 0.000 description 1
- 229960001630 diethylamino hydroxybenzoyl hexyl benzoate Drugs 0.000 description 1
- 229940120503 dihydroxyacetone Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229960000979 drometrizole Drugs 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 229960004697 enzacamene Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- CBZHHQOZZQEZNJ-UHFFFAOYSA-N ethyl 4-[bis(2-hydroxypropyl)amino]benzoate Chemical compound CCOC(=O)C1=CC=C(N(CC(C)O)CC(C)O)C=C1 CBZHHQOZZQEZNJ-UHFFFAOYSA-N 0.000 description 1
- 229940068171 ethyl hexyl salicylate Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000001997 free-flow electrophoresis Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- 229940046533 house dust mites Drugs 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 235000021109 kimchi Nutrition 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229940102398 methyl anthranilate Drugs 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- FMJSMJQBSVNSBF-UHFFFAOYSA-N octocrylene Chemical group C=1C=CC=CC=1C(=C(C#N)C(=O)OCC(CC)CCCC)C1=CC=CC=C1 FMJSMJQBSVNSBF-UHFFFAOYSA-N 0.000 description 1
- 229960000601 octocrylene Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- RCIMBBZXSXFZBV-UHFFFAOYSA-N piromidic acid Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CN=C1N1CCCC1 RCIMBBZXSXFZBV-UHFFFAOYSA-N 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229940100498 polysilicone-15 Drugs 0.000 description 1
- 229920002282 polysilicones-15 Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 210000001034 respiratory center Anatomy 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- CXVGEDCSTKKODG-UHFFFAOYSA-N sulisobenzone Chemical compound C1=C(S(O)(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 CXVGEDCSTKKODG-UHFFFAOYSA-N 0.000 description 1
- 229960000368 sulisobenzone Drugs 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 231100000617 superantigen Toxicity 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- QDWJJTJNXAKQKD-UHFFFAOYSA-N trihexyphenidyl hydrochloride Chemical compound Cl.C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 QDWJJTJNXAKQKD-UHFFFAOYSA-N 0.000 description 1
- ZQTYRTSKQFQYPQ-UHFFFAOYSA-N trisiloxane Chemical compound [SiH3]O[SiH2]O[SiH3] ZQTYRTSKQFQYPQ-UHFFFAOYSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2531/00—Reactions of nucleic acids characterised by
- C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
- C12Q2531/113—PCR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Otolaryngology (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Birds (AREA)
Abstract
Description
(a)臨床サンプルから分離した細胞外ベシクルから遺伝子を抽出するステップ;
(b)上記の遺伝子に対して塩基配列を解析するステップ;および
(c)上記の塩基配列解析を通して乳酸菌由来の細胞外ベシクルの分布が健常者に比べて低い場合、アトピー性皮膚炎の誘発危険性が高いと判定するステップ。
腸内の細菌であるシュードモナス・セドリナ(Pseudomonas cedrina)とシュードモナス・パナキス(Pseudomonas panacis)菌株から細胞外ベシクルを分離して、その特性を解析するために、上記の二つの菌株をLB broth(Luria−Bertani broth)でそれぞれ30℃、25℃の条件下で培養した。上記の細菌培養液を5,000gで30分間2回にかけて遠心分離した後、上澄み液を0.45μm bottle−top filter(Corning)を用いてフィルタリングして、溶出された試料をQuixStandTM(GE Healthcare Bio−Sciences AB)を用いて濃縮した。濃縮された試料を0.22μm bottle−top filter(Corning)を用いて、再び一回フィルタリングして細胞外ベシクルを分離しており、細胞外ベシクルのタンパク質の濃度はBCA assay(Thermo Scientific)を用いて定量した。
シュードモナス・パナキス(P.panacis)細菌とシュードモナス・パナキス(P.panacis)由来の細胞外ベシクルを経口投与した際に、体内での吸収、分布、および排泄の様相を評価するために、ジャクソン研究所から受けたC57BL/6J(6〜8−wk−old)雄のマウスを用いて実験を行った。
3−1.アトピー性皮膚炎患者の尿および血清から細胞外ベシクルの分離
上記の実施例2で細菌由来の細胞外ベシクルが体内に吸収された後、尿で排泄されて、血液にも分布して存在するという結果をもとに、アトピー性皮膚炎患者の尿と血清に存在する細菌由来の細胞外ベシクルを分離して、これに含むDNAを抽出した。
実施例3−1の方法でアトピー性皮膚炎患者の尿および血清に存在する細胞外ベシクルから分離したDNAを用いてメタゲノム解析を実施した。
実施例3−1の方法でアトピー性皮膚炎患者の尿と血清に存在する細菌由来の細胞外ベシクルからDNAを分離した後、実施例3−2の方法でメタゲノム解析を通して16S rDNAの塩基配列を解析して、上記の尿と血清に存在する細菌由来の細胞外ベシクルの分布を比べた。
実施例3−1および3−2の方法でアトピー性皮膚炎患者と健常者の尿に存在する細菌由来の細胞外ベシクルの分布の差を評価した。
上記の実施例4の結果を通してラクトバチルス目細菌およびラクトバチルス属細菌由来の細胞外ベシクルが健常者に比べてアトピー性皮膚炎患者の尿で顕著に減少されていることを確認したので、ラクトバチルス由来の細胞外ベシクルが免疫反応および炎症反応に及ぶ影響を調べるようにした。
炎症反応の発生で乳酸菌由来の細胞外ベシクルの効能を調べるために、皮膚上皮細胞株(HaCaT)2×105cellsに炎症疾患の主な原因因子として知られている黄色ブドウ球菌由来の細胞外ベシクル(S.aureus EV)およびニキビ菌(P.acnes EV)由来の細胞外ベシクルと上記の実施例5の方法で分離した乳酸菌由来の細胞外ベシクル(CJLP133 EV)をそれぞれ10ng〜25μg/mlの濃度で処理して12時間の間培養した後、上澄み液でTh17免疫反応を誘発するサイトカイン(cytokine)であるIL−6の分泌量をELISAを通して測定した。その結果、図21に示すように、黄色ブドウ球菌およびニキビ菌由来のベシクルに比べて、上記の乳酸菌由来の細胞外ベシクルを処理した場合、IL−6の分泌量がはるかに低く示された。
炎症細胞で黄色ブドウ球菌に由来の細胞外ベシクルによる炎症反応の発生に乳酸菌由来の細胞外ベシクルがどのような影響を及ぼすのかを調べてみようとした。まず、炎症細胞であるマウスの腹腔マクロファージ(Raw 264.7)に1μgの黄色ブドウ球菌由来の細胞外ベシクル(S.aureus)または10ng、100ng、または1μgの乳酸菌由来の細胞外ベシクル(CJLP133)を12時間の間処理した後、腹腔マクロファージから分泌される炎症性サイトカインであるIL−6とTNF−αの量を測定して比較した。その結果、図23に示すように、乳酸菌由来の細胞外ベシクルを処理した場合、濃度に関係なく黄色ブドウ球菌由来のベシクルを処理した場合に比べてIL−6およびTNF−αの分泌が顕著に減少した。これは黄色ブドウ球菌由来のベシクルに比べて乳酸菌由来の細胞外ベシクルが体内に吸収された際に、はるかに安全であることを意味する。
黄色ブドウ球菌由来の細胞外ベシクルによる皮膚上皮細胞の死滅で乳酸菌由来の細胞外ベシクルの死滅抑制効果を評価するために、皮膚上皮細胞に実施例6と同一な濃度および条件で乳酸菌由来の細胞外ベシクルを前処理した後、黄色ブドウ球菌由来のベシクル(S.aureus EV)を25μg濃度で24時間の間処理して、MTT assay(Sigman、アメリカ)を実施した。その結果、図25に示すように、黄色ブドウ球菌由来のベシクルによる皮膚上皮細胞の死滅が乳酸菌由来の細胞外ベシクルを0.1μg/mlまたは1μg/ml濃度で処理した場合、効率的に抑制されることを確認した。
緑膿菌(P.aeruginosa)はシュードモナス(Pseudomonas)属に属する主な病院性細菌として、抗生剤の耐性を起こりやすく、敗血症の主な原因細菌として知られていった。最近、緑膿菌由来の細胞外ベシクルが気道を通す繰り返す露出により、喘息、慢性閉鎖性肺疾患(COPD)、肺がんなどのような慢性肺疾患の主な原因因子として知られるようになった。このような背景の下で、緑膿菌由来のベシクルによる炎症反応の発生において乳酸菌由来の細胞外ベシクルの抗炎症の効果を評価しようとした。
上記の実施例6ないし8を通して、乳酸菌由来の細胞外ベシクルの黄色ブドウ球菌由来の細胞外ベシクルによる免疫調節、抗炎症、および皮膚細胞の死滅の抑制効果を確認したので、実際に乳酸菌由来の細胞外ベシクルの皮膚投与によるアトピー性皮膚炎の治療効果を評価するようにした。
乳酸菌由来の細胞外ベシクルの経口投与によるアトピー性皮膚炎の治療効果を評価するために、図31に示すプロトコルにより、SKH−1 hairlessマウスに10μgの濃度の黄色ブドウ球菌由来のベシクル(S.aureus EV)を週3回ずつ4週間、繰り返し塗布してアトピー性皮膚炎モデルを製作して、黄色ブドウ球菌由来のベシクルを塗布する12時間前に乳酸菌由来の細胞外ベシクル(CJLP133 EV)を経口で投与してアトピー性皮膚炎の発生に対する治療の効果を観察した。
乳酸菌由来の細胞外ベシクルの高容量反復投与による毒性を評価するために、図34に図示した方法で、週3回、4週間(総12回)、乳酸菌由来の細胞外ベシクル(CJLP133)の500μgを経口で投与した。その後、ベシクルを投与していない対照群と乳酸菌由来のベシクルを経口投与した群でそれぞれのマウスの体重、飼料の摂取量、体温を測定した。
<210>1
<211>19
<212>DNA
<213>Artificial Sequence
<220>
<223>16s rDNA fusion primer_27F
<400>1
gagtttgatc mtggctcag 19
<210>2
<211>17
<212>DNA
<213>Artificial Sequence
<220>
<223>16s rDNA fusion primer_518R
<400>2
wttaccgcgg ctgctgg 17
Claims (39)
- 乳酸菌由来の細胞外ベシクルを有効成分として含む、炎症疾患の予防または治療用の薬学的な組成物。
- 上記の乳酸菌はラクトバチルス(Lactobacillales)目の細菌であることを特徴とする、請求項1に記載の薬学的な組成物。
- 上記のラクトバチルス(Lactobacillales)目の細菌はラクトコッカス(Lactococcus)、ラクトバチルス(Lactobacillus)、またはリューコノストック(Leuconostoc)属の細菌であることを特徴とする、請求項2に記載の薬学的な組成物。
- 上記のラクトバチルス(Lactobacillus)属の細菌はラクトバチルス・プランタルム(Lactobacillus plantarum)であることを特徴とする、請求項3に記載の薬学的な組成物。
- 上記の細胞外ベシクルは平均直径が10〜300nmであることを特徴とする、請求項1に記載の薬学的な組成物。
- 上記の細胞外ベシクルは乳酸菌培養液から分離されることを特徴とする、請求項1に記載の薬学的な組成物。
- 上記の細胞外ベシクルは乳酸菌で自然的または人工的に分泌されることを特徴とする、請求項1に記載の薬学的組成物。
- 上記の炎症疾患はアトピー性皮膚炎、慢性鼻炎、慢性副鼻腔炎、喘息、慢性閉塞性肺疾患(COPD)、および敗血症からなる群より選ばれる疾患であることを特徴とする、請求項1に記載の薬学的な組成物。
- 乳酸菌由来の細胞外ベシクルを有効成分として含む、炎症疾患の改善用の化粧料の組成物。
- 上記の乳酸菌はラクトバチルス(Lactobacillales)目の細菌であることを特徴とする、請求項9に記載の化粧料の組成物。
- 上記のラクトバチルス(Lactobacillales)目の細菌はラクトコッカス(Lactococcus)、ラクトバチルス(Lactobacillus)、またはリューコノストック(Leuconostoc)属の細菌であることを特徴とする、請求項10に記載の化粧料の組成物。
- 上記のラクトバチルス(Lactobacillus)属の細菌はラクトバチルス・プランタルム(Lactobacillus plantarum)であることを特徴とする、請求項11に記載の化粧料の組成物。
- 上記の細胞外ベシクルは平均直径が10〜300nmであることを特徴とする、請求項9に記載の化粧料の組成物。
- 上記の細胞外ベシクルは乳酸菌培養液から分離されることを特徴とする、請求項9に記載の化粧料の組成物
- 上記の細胞外ベシクルは乳酸菌から自然的または人工的に分泌されることを特徴とする、請求項9に記載の化粧料の組成物。
- 上記の炎症疾患はアトピー性皮膚炎、慢性鼻炎、慢性副鼻腔炎、喘息、慢性閉塞性肺疾患(COPD)、および敗血症からなる群より選ばれる疾患であることを特徴とする、請求項9に記載の化粧料の組成物。
- 乳酸菌由来の細胞外ベシクルを有効成分として含む、炎症疾患の改善用の健康機能食品の組成物。
- 上記の乳酸菌はラクトバチルス(Lactobacillales)目の細菌であることを特徴とする、請求項17に記載の健康機能食品の組成物。
- 上記のラクトバチルス(Lactobacillales)目の細菌はラクトコッカス(Lactococcus)、ラクトバチルス(Lactobacillus)、またはリューコノストック(Leuconostoc)属の細菌であることを特徴とする、請求項18に記載の健康機能食品の組成物。
- 上記のラクトバチルス(Lactobacillus)属の細菌はラクトバチルス・プランタルム(Lactobacillus plantarum)であることを特徴とする、請求項19に記載の健康機能食品の組成物。
- 上記の細胞外ベシクルは平均直径が10〜300nmであることを特徴とする、請求項17に記載の健康機能食品の組成物。
- 上記の細胞外ベシクルは乳酸菌培養液から分離されることを特徴とする、請求項17に記載の健康機能食品の組成物。
- 上記の細胞外ベシクルは乳酸菌から自然的または人工的に分泌されることを特徴とする、請求項17に記載の健康機能食品の組成物。
- 上記の炎症疾患はアトピー性皮膚炎、慢性鼻炎、慢性副鼻腔炎、喘息、慢性閉塞性肺疾患(COPD)、および敗血症からなる群より選ばれる疾患であることを特徴とする、請求項17に記載の健康機能食品の組成物。
- 乳酸菌由来の細胞外ベシクルを有効成分として含む、炎症疾患の予防または治療用の吸入剤の組成物。
- 上記の乳酸菌はラクトバチルス(Lactobacillales)目の細菌であることを特徴とする、請求項25に記載の吸入剤の組成物。
- 上記のラクトバチルス(Lactobacillales)目の細菌はラクトコッカス(Lactococcus)、ラクトバチルス(Lactobacillus)、またはリューコノストック(Leuconostoc)属の細菌であることを特徴とする、請求項26に記載の吸入剤の組成物。
- 上記のラクトバチルス(Lactobacillus)属の細菌はラクトバチルス・プランタルム(Lactobacillus plantarum)であることを特徴とする、請求項25に記載の吸入剤の組成物。
- 上記の細胞外ベシクルは平均直径が10〜300nmであることを特徴である、請求項27に記載の吸入剤の組成物。
- 上記の細胞外ベシクルは乳酸菌培養液から分離されることを特徴とする、請求項25に記載の吸入剤の組成物。
- 上記の細胞外ベシクルは乳酸菌から自然的または人工的に分泌されることを特徴とする、請求項25に記載の吸入剤の組成物。
- 上記の炎症疾患はアトピー性皮膚炎、慢性鼻炎、慢性副鼻腔炎、喘息、慢性閉塞性肺疾患(COPD)、および敗血症からなる群より選ばれる疾患であることを特徴とする、請求項25に記載の吸入剤の組成物。
- 下記のステップを含む、アトピー性皮膚炎の診断方法:
(a)臨床サンプルで分離した細胞外ベシクルから遺伝子を抽出するステップ;
(b)上記の遺伝子に対して塩基配列を解析するステップ;および
(c)上記の塩基配列の解析を通して乳酸菌由来の細胞外ベシクルの分布が健常者に比べて低い場合、アトピー性皮膚炎の誘発危険性が高いと判定するステップ。 - 上記の遺伝子はDNAまたはRNAであることを特徴とする、請求項33に記載の診断方法。
- 上記の臨床サンプルは尿または血液であることを特徴とする、請求項33に記載の診断方法。
- 上記の塩基配列の解析はポリメラーゼ連鎖反応(PCR)を通して行われることを特徴とする、請求項33に記載の診断方法。
- 乳酸菌由来の細胞外ベシクルを有効成分として含む組成物を個体に投与するステップを含む、炎症疾患の予防または治療方法。
- 乳酸菌由来の細胞外ベシクルの炎症疾患の予防または治療用途。
- 乳酸菌由来の細胞外ベシクルのアトピー性皮膚炎の診断用途。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20150033698 | 2015-03-11 | ||
KR10-2015-0033698 | 2015-03-11 | ||
KR10-2016-0029069 | 2016-03-10 | ||
KR1020160029069A KR20160110232A (ko) | 2015-03-11 | 2016-03-10 | 유산균 유래 세포밖 소포체를 유효성분으로 포함하는 염증질환의 예방 또는 치료용 조성물 |
PCT/KR2016/002473 WO2016144139A2 (ko) | 2015-03-11 | 2016-03-11 | 유산균 유래 세포밖 소포체를 유효성분으로 포함하는 염증질환의 예방 또는 치료용 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018511583A true JP2018511583A (ja) | 2018-04-26 |
JP6700297B2 JP6700297B2 (ja) | 2020-05-27 |
Family
ID=57080496
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017547484A Active JP6700297B2 (ja) | 2015-03-11 | 2016-03-11 | 乳酸菌由来の細胞外ベシクルを有効成分として含む、炎症疾患の予防または治療用の組成物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US10406184B2 (ja) |
EP (1) | EP3269378B1 (ja) |
JP (1) | JP6700297B2 (ja) |
KR (3) | KR20160110232A (ja) |
CN (1) | CN107750161B (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019528688A (ja) * | 2016-08-12 | 2019-10-17 | エムディー ヘルスケア インコーポレイテッドMd Healthcare Inc. | バチルス属細菌由来ナノ小胞およびその用途 |
CN113260372A (zh) * | 2018-12-31 | 2021-08-13 | Md保健株式会社 | 衍生自副干酪乳杆菌的囊泡及其用途 |
JP2021521898A (ja) * | 2018-05-04 | 2021-08-30 | メディトックス インク. | 標的蛋白質をコーディングするポリヌクレオチドを含む組み換え微生物に由来する細胞外小嚢及びその用途 |
JP2022511913A (ja) * | 2018-12-10 | 2022-02-01 | エムディー ヘルスケア インコーポレイテッド | ワイセラ属細菌由来のナノ小胞およびその用途 |
WO2023229034A1 (ja) * | 2022-05-27 | 2023-11-30 | アサヒグループホールディングス株式会社 | 乳酸菌由来の外膜小胞を含有するfpr2作動剤 |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016077327A1 (en) | 2014-11-10 | 2016-05-19 | The Procter & Gamble Company | Personal care compositions with two benefit phases |
MX2017006148A (es) | 2014-11-10 | 2017-07-27 | Procter & Gamble | Composiciones para el cuidado personal con dos fases beneficas. |
US10966916B2 (en) | 2014-11-10 | 2021-04-06 | The Procter And Gamble Company | Personal care compositions |
WO2018030732A1 (ko) * | 2016-08-12 | 2018-02-15 | 주식회사 엠디헬스케어 | 바실러스 속 세균 유래 나노소포 및 이의 용도 |
KR20180019474A (ko) * | 2016-08-16 | 2018-02-26 | 주식회사 엠디헬스케어 | 락토바실러스 플란타룸 유래 소포를 포함하는 정신질환 예방 또는 치료용 조성물 |
KR101833348B1 (ko) * | 2016-12-26 | 2018-03-02 | 주식회사 엠디헬스케어 | 세균 메타게놈 분석을 통한 유방암 진단방법 |
KR101833504B1 (ko) * | 2016-12-26 | 2018-03-05 | 주식회사 엠디헬스케어 | 세균 메타게놈 분석을 통한 폐암 진단방법 |
WO2018124744A1 (ko) * | 2016-12-28 | 2018-07-05 | 주식회사 엠디헬스케어 | 세균 메타게놈 분석을 통한 간질환 진단 방법 |
KR101940426B1 (ko) * | 2016-12-28 | 2019-01-18 | 주식회사 엠디헬스케어 | 세균 메타게놈 분석을 통한 대장종양 진단 방법 |
WO2018124735A1 (ko) * | 2016-12-28 | 2018-07-05 | 주식회사 엠디헬스케어 | 세균 메타게놈 분석을 통한 대장종양 진단 방법 |
KR101940445B1 (ko) * | 2017-02-24 | 2019-01-18 | 주식회사 엠디헬스케어 | 세균 메타게놈 분석을 통한 당뇨병 진단 방법 |
WO2018155950A1 (ko) * | 2017-02-24 | 2018-08-30 | 주식회사 엠디헬스케어 | 세균 메타게놈 분석을 통한 당뇨병 진단 방법 |
WO2018225945A1 (ko) * | 2017-06-07 | 2018-12-13 | 주식회사 엠디헬스케어 | 미생물 메타게놈 분석을 통한 아토피피부염 진단방법 |
KR102348048B1 (ko) * | 2017-06-29 | 2022-01-10 | (주)아모레퍼시픽 | 유산균 유래의 세포밖 베지클을 포함하는 항노화용 조성물 |
WO2019004668A1 (ko) | 2017-06-30 | 2019-01-03 | 주식회사 엠디헬스케어 | 프로테우스 속 세균 유래 나노소포 및 이의 용도 |
WO2019079405A1 (en) | 2017-10-20 | 2019-04-25 | The Procter & Gamble Company | AEROSOL FOAMING CLEANSER FOR THE SKIN |
CN111212625B (zh) | 2017-10-20 | 2023-05-23 | 宝洁公司 | 气溶胶泡沫洁肤剂 |
KR102335710B1 (ko) * | 2017-10-31 | 2021-12-07 | (주)아모레퍼시픽 | 유산균 유래의 세포밖 베지클을 포함하는 면역조절용 조성물 |
KR102095355B1 (ko) * | 2018-01-12 | 2020-03-31 | 주식회사 엠디헬스케어 | 모르가넬라 속 세균 유래 나노소포 및 이의 용도 |
KR102282490B1 (ko) | 2018-01-12 | 2021-07-28 | 주식회사 엠디헬스케어 | 패칼리박테리움 프라우스니찌 유래 나노소포 및 이의 용도 |
KR102250596B1 (ko) * | 2018-02-02 | 2021-05-12 | 주식회사 엠디헬스케어 | 비피도박테리움 속 세균 유래 나노소포 및 이의 용도 |
KR102063196B1 (ko) * | 2018-02-06 | 2020-01-07 | 주식회사 엠디헬스케어 | 세균 메타게놈 분석을 통한 과민성장증후군 진단방법 |
KR102194286B1 (ko) * | 2018-02-08 | 2020-12-22 | 주식회사 엠디헬스케어 | 락토코커스 속 세균 유래 나노소포 및 이의 용도 |
WO2019156449A1 (ko) * | 2018-02-08 | 2019-08-15 | 주식회사 엠디헬스케어 | 락토코커스 속 세균 유래 나노소포 및 이의 용도 |
KR102194274B1 (ko) * | 2018-02-20 | 2020-12-22 | 주식회사 엠디헬스케어 | 카테니박테리움 속 세균 유래 나노소포 및 이의 용도 |
WO2019164230A1 (ko) * | 2018-02-21 | 2019-08-29 | 주식회사 엠디헬스케어 | 큐프리아비더스 속 세균 유래 나노소포 및 이의 용도 |
KR102087105B1 (ko) * | 2018-02-21 | 2020-03-10 | 주식회사 엠디헬스케어 | 큐프리아비더스 속 세균 유래 나노소포 및 이의 용도 |
US11771742B2 (en) | 2018-02-21 | 2023-10-03 | Md Healthcare Inc. | Nano-vesicles derived from genus cupriavidus bacteria and use thereof |
WO2019172598A1 (ko) * | 2018-03-05 | 2019-09-12 | 주식회사 엠디헬스케어 | 락토바실러스 속 세균 유래 나노소포 및 이의 용도 |
KR102101692B1 (ko) * | 2018-03-05 | 2020-04-20 | 주식회사 엠디헬스케어 | 락토바실러스 속 세균 유래 나노소포 및 이의 용도 |
KR102118989B1 (ko) | 2018-03-05 | 2020-06-05 | 주식회사 엠디헬스케어 | 엔히드로박터 세균 유래 나노소포 및 이의 용도 |
KR102118203B1 (ko) * | 2018-03-06 | 2020-06-02 | 주식회사 엠디헬스케어 | 코프로코커스 속 세균 유래 나노소포 및 이의 용도 |
KR102553825B1 (ko) * | 2018-05-04 | 2023-07-13 | (주)메디톡스 | 표적 단백질을 코딩하는 폴리뉴클레오티드를 포함하는 재조합 미생물로부터 유래한 세포외 소낭 및 그의 용도 |
PL3801061T3 (pl) * | 2018-06-01 | 2023-10-09 | Nzym Deutschland Gmbh | Mikropęcherzyki pochodzące ze sfermentowanych produktów pochodzenia roślinnego, sposób ich przygotowania i zastosowania |
KR102183389B1 (ko) * | 2018-06-28 | 2020-11-26 | 주식회사 엠디헬스케어 | 세균 메타게놈 분석을 통한 염증성장염 진단 방법 |
US20200040373A1 (en) * | 2018-08-06 | 2020-02-06 | The Procter & Gamble Company | Method of Screening Skin Products |
WO2020112486A1 (en) | 2018-11-29 | 2020-06-04 | The Procter & Gamble Company | Methods for screening personal care products |
KR102356626B1 (ko) * | 2018-12-10 | 2022-01-28 | 주식회사 엠디헬스케어 | 웨이셀라 속 세균 유래 나노소포 및 이의 용도 |
KR102223406B1 (ko) * | 2018-12-10 | 2021-03-05 | 주식회사 엠디헬스케어 | 코리네박테리움 속 세균 유래 나노소포 및 이의 용도 |
KR102651296B1 (ko) * | 2018-12-28 | 2024-03-26 | 씨제이제일제당 (주) | 헬리코박터 파일로리 감염에 의해 발생한 위암의 예방 또는 개선용 김치를 포함하는 식품 조성물 |
US10987386B2 (en) * | 2018-12-31 | 2021-04-27 | Md Healthcare Inc. | Method for treating inflammation or cancer using extracellular vesicles derived from Lactobacillus paracasei |
KR102328744B1 (ko) * | 2019-10-08 | 2021-11-22 | 한국식품연구원 | 락토바실러스 플란타럼 균주를 유효성분으로 포함하는 호흡기 질환 개선용 조성물 |
JP2023513394A (ja) * | 2020-01-20 | 2023-03-30 | イーブイ、セル、バイオテック、(コアンチョウ)、カンパニー、リミテッド | 細胞外小胞及びその皮膚製品における使用 |
KR102264827B1 (ko) * | 2020-08-31 | 2021-06-15 | 주식회사 케이티앤지 | 익모초 추출물 및 신규 락토바실러스 플란타룸(Lactobacillus plantarum) KC3 균주로 구성된 조합을 유효성분으로 함유하는 면역장애, 호흡기 질환, 알레르기 또는 천식의 예방 및 치료용 조성물 |
WO2022055250A1 (ko) * | 2020-09-08 | 2022-03-17 | 주식회사 바이오솔루션 | 수득률이 향상된 미생물 유래 세포 외 소포체의 제조 방법 및 이의 방법으로 제조된 세포 외 소포체를 포함하는 피부 상태 개선용 조성물 |
JP2023547088A (ja) * | 2020-10-21 | 2023-11-09 | カンステム バイオテック カンパニー リミテッド | 多能性幹細胞由来の皮膚オルガノイドを用いたアトピー性皮膚炎モデルの作製方法 |
KR20220061555A (ko) | 2020-11-06 | 2022-05-13 | (주)프로스테믹스 | 신규한 락토바실러스 속 균주 및 상기 균주 유래 세포외 소포의 용도 |
KR102332021B1 (ko) | 2020-11-19 | 2021-12-01 | 주식회사 현대바이오랜드 | A2 베타 카제인 단백질이 포함된 배지 조성물을 이용한 아미노바이오틱스의 제조방법 및 이를 통해 제조한 아미노바이오틱스 |
US20240009255A1 (en) * | 2020-11-30 | 2024-01-11 | Md Healthcare Inc. | Composition for preventing, treating or ameliorating eosinophilic inflammatory diseases or th2 hypersensitivity immune diseases comprising lactococcus lactis-derived vesicles |
KR102448547B1 (ko) | 2020-12-10 | 2022-09-30 | 대한민국 | 과수화상병 방제용 슈도모나스 세드리나 s26-32 균주 및 이의 용도 |
WO2022139531A1 (ko) * | 2020-12-23 | 2022-06-30 | 주식회사 리스큐어바이오사이언시스 | 류코노스톡 시트리움 유래 세포밖 소포체를 유효성분으로 포함하는 지방간 개선, 예방 또는 치료용 조성물 |
WO2022139532A1 (ko) * | 2020-12-23 | 2022-06-30 | 주식회사 리스큐어바이오사이언시스 | 와이셀라 헬레니카 유래 세포밖 소포체를 유효성분으로 포함하는 지방간 개선, 예방 또는 치료용 조성물 |
WO2022164012A1 (ko) * | 2021-02-01 | 2022-08-04 | 주식회사 엠디헬스케어 | 락토바실러스 파라카제이 유래 소포를 포함하는 바이러스 감염 질환 또는 호흡기 질환의 예방, 치료, 또는 개선용 조성물 |
KR102439760B1 (ko) * | 2021-03-09 | 2022-09-02 | 주식회사 오라팜 | 상기도 감염균 질환 예방 및 치료를 위한 조성물 |
TWI793595B (zh) * | 2021-05-07 | 2023-02-21 | 葡萄王生技股份有限公司 | 益生菌胞外泌體及其用途 |
CN115305211A (zh) * | 2021-05-07 | 2022-11-08 | 葡萄王生技股份有限公司 | 益生菌胞外泌体及其用途 |
EP4349351A1 (en) * | 2021-06-03 | 2024-04-10 | MD Healthcare Inc. | Lactobacillus plantarum-derived vesicle and use thereof |
KR102661178B1 (ko) * | 2021-06-03 | 2024-04-29 | 주식회사 엠디헬스케어 | 락토바실러스 파라카세이 유래 세포외소포를 포함하는 안질환 예방 또는 치료용 조성물 |
WO2022255784A1 (ko) * | 2021-06-03 | 2022-12-08 | 주식회사 엠디헬스케어 | 락토바실러스 람노수스 유래 소포 및 이의 용도 |
EP4349354A1 (en) * | 2021-06-03 | 2024-04-10 | MD Healthcare Inc. | Extracellular vesicles derived from lactobacillus bacteria, and use thereof |
WO2022255746A1 (ko) * | 2021-06-03 | 2022-12-08 | 주식회사 엠디헬스케어 | 락토바실러스 아시도필러스 유래 소포 및 이의 용도 |
JP2024520165A (ja) * | 2021-06-07 | 2024-05-21 | エムディー ヘルスケア インコーポレイテッド | ロイコノストック細菌由来小胞を含む炎症疾患あるいはがんの予防または治療用組成物 |
WO2023113541A1 (en) * | 2021-12-16 | 2023-06-22 | Enterobiome Inc. | Pharmaceutical composition for preventing or treating cancer or inflammatory disease |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006519014A (ja) * | 2003-01-30 | 2006-08-24 | バイオガイア・エイビー | 乳酸菌からの抗炎症活性 |
KR20070078107A (ko) * | 2006-01-25 | 2007-07-31 | 주식회사 알엔에이 | 알러지 질환 예방 및 치료를 위한 유산균 |
JP2010047504A (ja) * | 2008-08-20 | 2010-03-04 | Nippon Meat Packers Inc | アトピー性皮膚炎緩和剤 |
KR20110082481A (ko) * | 2010-01-11 | 2011-07-19 | 포항공과대학교 산학협력단 | 발효식품에서 유래된 세포밖 소포체를 포함하는 조성물 및 이의 용도 |
JP2012533319A (ja) * | 2009-07-22 | 2012-12-27 | シージェイ チェイルジェダン コーポレーション | 新規なラクトバチルス・プランタラム及びこれを含む組成物 |
JP2013503858A (ja) * | 2009-09-04 | 2013-02-04 | イオン メディックス インコーポレイテッド | グラム陽性細菌由来細胞外ベシクル及びその用途 |
KR20130034764A (ko) * | 2011-09-29 | 2013-04-08 | 정용현 | 신규한 균주로 항알러지, 아토피성 피부염 개선 및 면역력증진 기능을 갖는 Lactobacillus plantarum K-1과 이를 함유하는 미생물제제 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2589391B1 (en) * | 2010-07-01 | 2018-11-14 | Rosetta Exosome Co., Ltd. | Bacterial cell-derived microvesicles for use in a method of treating cancer |
KR101726488B1 (ko) * | 2015-02-23 | 2017-04-13 | 이화여자대학교 산학협력단 | 바실러스 속 세균 유래 세포밖 소포체를 포함하는 임신관련 질환 치료용 조성물 |
-
2016
- 2016-03-10 KR KR1020160029069A patent/KR20160110232A/ko active Application Filing
- 2016-03-11 US US15/556,953 patent/US10406184B2/en active Active
- 2016-03-11 CN CN201680014982.7A patent/CN107750161B/zh active Active
- 2016-03-11 JP JP2017547484A patent/JP6700297B2/ja active Active
- 2016-03-11 EP EP16762026.9A patent/EP3269378B1/en active Active
- 2016-12-08 KR KR1020160166788A patent/KR20170000369A/ko not_active Application Discontinuation
-
2017
- 2017-02-01 KR KR1020170014513A patent/KR101862507B1/ko active IP Right Grant
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006519014A (ja) * | 2003-01-30 | 2006-08-24 | バイオガイア・エイビー | 乳酸菌からの抗炎症活性 |
KR20070078107A (ko) * | 2006-01-25 | 2007-07-31 | 주식회사 알엔에이 | 알러지 질환 예방 및 치료를 위한 유산균 |
JP2010047504A (ja) * | 2008-08-20 | 2010-03-04 | Nippon Meat Packers Inc | アトピー性皮膚炎緩和剤 |
JP2012533319A (ja) * | 2009-07-22 | 2012-12-27 | シージェイ チェイルジェダン コーポレーション | 新規なラクトバチルス・プランタラム及びこれを含む組成物 |
JP2013503858A (ja) * | 2009-09-04 | 2013-02-04 | イオン メディックス インコーポレイテッド | グラム陽性細菌由来細胞外ベシクル及びその用途 |
KR20110082481A (ko) * | 2010-01-11 | 2011-07-19 | 포항공과대학교 산학협력단 | 발효식품에서 유래된 세포밖 소포체를 포함하는 조성물 및 이의 용도 |
KR20130034764A (ko) * | 2011-09-29 | 2013-04-08 | 정용현 | 신규한 균주로 항알러지, 아토피성 피부염 개선 및 면역력증진 기능을 갖는 Lactobacillus plantarum K-1과 이를 함유하는 미생물제제 |
Non-Patent Citations (5)
Title |
---|
FASEB J., vol. 29, JPN6018034247, November 2014 (2014-11-01), pages 684 - 695, ISSN: 0004124847 * |
J. HEPATOL., vol. vol. 60, No. 1, Suppl. 1, JPN6018034246, April 2014 (2014-04-01), pages 270, ISSN: 0004124846 * |
J. TRANSL. MED., vol. 12, no. 125, JPN6018034250, 2014, pages 1 - 11, ISSN: 0004124850 * |
NEW FOOD INDUSTRY, vol. 43, no. 5, JPN6018034248, 2001, pages 11 - 16, ISSN: 0004124848 * |
野白喜久雄ほか 編, 醸造の事典, vol. 第1版, JPN6018034249, 1988, pages 421 - 434, ISSN: 0004124849 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019528688A (ja) * | 2016-08-12 | 2019-10-17 | エムディー ヘルスケア インコーポレイテッドMd Healthcare Inc. | バチルス属細菌由来ナノ小胞およびその用途 |
JP2021521898A (ja) * | 2018-05-04 | 2021-08-30 | メディトックス インク. | 標的蛋白質をコーディングするポリヌクレオチドを含む組み換え微生物に由来する細胞外小嚢及びその用途 |
JP7297872B2 (ja) | 2018-05-04 | 2023-06-26 | メディトックス インク. | 標的蛋白質をコーディングするポリヌクレオチドを含む組み換え微生物に由来する細胞外小嚢及びその用途 |
JP2022511913A (ja) * | 2018-12-10 | 2022-02-01 | エムディー ヘルスケア インコーポレイテッド | ワイセラ属細菌由来のナノ小胞およびその用途 |
JP7240031B2 (ja) | 2018-12-10 | 2023-03-15 | エムディー ヘルスケア インコーポレイテッド | ワイセラ属細菌由来のナノ小胞およびその用途 |
CN113260372A (zh) * | 2018-12-31 | 2021-08-13 | Md保健株式会社 | 衍生自副干酪乳杆菌的囊泡及其用途 |
JP2022514977A (ja) * | 2018-12-31 | 2022-02-16 | エムディー ヘルスケア インコーポレイテッド | ラクトバチルス・パラカゼイ由来の小胞及びその用途 |
WO2023229034A1 (ja) * | 2022-05-27 | 2023-11-30 | アサヒグループホールディングス株式会社 | 乳酸菌由来の外膜小胞を含有するfpr2作動剤 |
Also Published As
Publication number | Publication date |
---|---|
CN107750161A (zh) | 2018-03-02 |
KR101862507B1 (ko) | 2018-05-29 |
CN107750161B (zh) | 2022-01-14 |
US10406184B2 (en) | 2019-09-10 |
KR20170000369A (ko) | 2017-01-02 |
EP3269378A4 (en) | 2018-04-18 |
EP3269378A2 (en) | 2018-01-17 |
US20180055894A1 (en) | 2018-03-01 |
EP3269378B1 (en) | 2020-08-05 |
JP6700297B2 (ja) | 2020-05-27 |
KR20160110232A (ko) | 2016-09-21 |
KR20170015958A (ko) | 2017-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6700297B2 (ja) | 乳酸菌由来の細胞外ベシクルを有効成分として含む、炎症疾患の予防または治療用の組成物 | |
JP6839265B2 (ja) | バチルス属細菌由来ナノ小胞およびその用途 | |
US20210030821A1 (en) | Nanovesicles derived from lactobacillus sp. bacteria, and use thereof | |
US11883440B2 (en) | Nanovesicle derived from Proteus genus bacteria, and use thereof | |
US11529377B2 (en) | Nano-vesicles derived from genus Sphingomonas bacteria and use thereof | |
US10888591B2 (en) | Nano-vesicles derived from genus Micrococcus bacteria and use thereof | |
US20210052675A1 (en) | Nanovesicles derived from bacteria of lactococcus genus and use thereof | |
KR20190106723A (ko) | 코프로코커스 속 세균 유래 나노소포 및 이의 용도 | |
KR20190103965A (ko) | 스트렙토코커스 속 세균 유래 나노소포 및 이의 용도 | |
US20220090171A1 (en) | Nanovesicles derived from bacteria of genus deinococcus, and use thereof | |
US20230287517A1 (en) | Nanovesicles derived from collinsella sp. bacteria, and use thereof | |
US20220047648A1 (en) | Nanovesicles derived from bacteria of genus rhodococcus, and use thereof | |
US20210332420A1 (en) | Nano-vesicle derived from corynebacterium sp. bacteria and use thereof | |
EP3910071A1 (en) | Nanovesicles derived from bacteria of genus rhodococcus, and use thereof | |
US20230158082A1 (en) | Nanovesicles derived from coprococcus sp. bacteria, and use thereof | |
KR20190103029A (ko) | 아토포비움 속 세균 유래 나노소포 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171130 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171130 |
|
RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20180124 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20180124 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180905 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181205 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20181206 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190319 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190618 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190819 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191001 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191219 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200402 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200430 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6700297 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |